Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

1. Levothyroxine to increase live births in euthyroid women with thyroid antibodies trying to conceive: the TABLET RCT

Levothyroxine to increase live births in euthyroid women with thyroid antibodies trying to conceive: the TABLET RCT Levothyroxine to increase live births in euthyroid women with thyroid antibodies trying to conceive: the TABLET RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This large trial showed levothyroxine therapy in a dose of 50mcg per day did not improve live birth rates in euthyroid women with thyroid antibodies. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & . Rima K Dhillon-Smith 1, 2, 3 , Lee J Middleton 4 , Kirandeep K Sunner 4 , Versha Cheed 4 , Krys Baker 5 , Samantha Farrell-Carver 4 , Ruth Bender

2019 NIHR HTA programme

2. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer

Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer Current guidelines recommend that women delay pregnancy for 6 to 12 months after the receipt of radioactive iodine treatment (RAIT) following thyroidectomy for differentiated thyroid carcinoma. Although concerns exist regarding the risks associated with pregnancy after RAIT, no large-scale study, to date, has investigated the association between RAIT and pregnancy (...) outcomes.To investigate whether RAIT was associated with increases in adverse pregnancy outcomes among South Korean women who received RAIT after thyroidectomy for thyroid cancer and to evaluate the appropriate interval between RAIT and conception.This population-based cohort study used the Health Insurance Review and Assessment database of South Korea to identify a total of 111 459 women of childbearing age (20-49 years) who underwent thyroidectomy for the treatment of differentiated thyroid carcinoma

2019 EvidenceUpdates

3. Thyroid Cancer

Thyroid Cancer Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † S. Filetti 1 , C. Durante 1 , D. Hartl 2 , S. Leboulleux 3 , L.D. Locati 4 , K. Newbold 5 , M.G. Papotti 6 , A. Berruti 7 , on behalf of the ESMO Guidelines Committee* 1 Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy; 2 Department of Head and Neck Oncology, Gustave Roussy and Université Paris Saclay, Villejuif; 3 Department of Nuclear (...) : clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: February 2008, last update September 2019. This publication supersedes the previously published version—Ann Oncol 2012; 23 (Suppl. 7): vii110–vii119. Running header: ESMO Clinical Practice Guidelines thyroid cancer Word count: 11 701 (excluding key message, references, tables & figures) Key words: papillary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, management Key message (online only): ©

2019 European Society for Medical Oncology

4. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. (PubMed)

Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. To explore whether thyroid stimulating hormone (TSH) concentration in patients with a diagnosis of hypothyroidism is associated with increased all cause mortality and a higher risk of cardiovascular disease and fractures.Retrospective cohort study.The Health Improvement Network (THIN), a database of electronic patient records from UK primary

2019 BMJ

5. Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis. (PubMed)

Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis. Maternal hypothyroidism and hyperthyroidism are risk factors for preterm birth. Milder thyroid function test abnormalities and thyroid autoimmunity are more prevalent, but it remains controversial if these are associated with preterm birth.To study if maternal thyroid function test abnormalities and thyroid autoimmunity are risk factors for preterm birth.Studies (...) were identified through a search of the Ovid MEDLINE, EMBASE, Web of Science, the Cochrane Central Register of Controlled Trials, and Google Scholar databases from inception to March 18, 2018, and by publishing open invitations in relevant journals. Data sets from published and unpublished prospective cohort studies with data on thyroid function tests (thyrotropin [often referred to as thyroid-stimulating hormone or TSH] and free thyroxine [FT4] concentrations) or thyroid peroxidase (TPO) antibody

2019 JAMA

6. Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system

Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system The AJCC/UICC classification is widely used for predicting survival in papillary thyroid cancer (PTC), but has not been evaluated as a predictor of recurrence. The hypothesis of this study was that the eighth edition of the AJCC system can be used in this novel way.All patients in the study underwent surgery for PTC at a high-volume endocrine surgery centre in France between 1985 and 2015

2019 EvidenceUpdates

7. Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism. (PubMed)

Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism. Thyroid disease is the second most common endocrine disorder affecting women of reproductive age. Subclinical hypothyroidism is diagnosed by an elevated thyroid-stimulating hormone concentration with a normal concentration of free thyroxine hormone. Autoimmune thyroid disease (ATD) is diagnosed by the presence of thyroid autoantibodies, regardless of thyroid hormone levels (...) . Thyroxine may be a useful treatment for subfertile women with these two specific types of thyroid disease for improving pregnancy outcomes during assisted reproduction.To evaluate the efficacy and harms of levothyroxine replacement in subfertile women with subclinical hypothyroidism or with normal thyroid function and thyroid autoimmunity (euthyroid autoimmune thyroid disease, or euthyroid ATD) undergoing assisted reproduction.We searched the Cochrane Gynaecology and Fertility (CGF) Group specialised

2019 Cochrane

8. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. (PubMed)

Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. What are the benefits and harms of thyroid hormones for adults with subclinical hypothyroidism (SCH)? This guideline was triggered by a recent systematic review of randomised controlled trials, which could alter practice.Current guidelines tend to recommend thyroid hormones for adults with thyroid stimulating hormone (TSH) levels >10 mIU/L and for people with lower TSH values who are young, symptomatic (...) , or have specific indications for prescribing.The guideline panel issues a strong recommendation against thyroid hormones in adults with SCH (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying to become pregnant or patients with TSH >20 mIU/L. It may not apply to patients with severe symptoms or young adults (such as those ≤30 years old).A guideline panel including patients, clinicians, and methodologists produced this recommendation in adherence

2019 BMJ

9. A Perioperative Small Dose of Dexamethasone Enhances Postoperative Recovery by Reducing Volume and Inflammatory Contents in Wound Drainage After Thyroid Surgery: A Double-Blinded, Randomized, Prospective Study

A Perioperative Small Dose of Dexamethasone Enhances Postoperative Recovery by Reducing Volume and Inflammatory Contents in Wound Drainage After Thyroid Surgery: A Double-Blinded, Randomized, Prospective Study The aims of this study were to assess the effect of perioperative dexamethasone on postoperative thyroid surgery recovery using measures of wound drainage volume and C-reactive protein (CRP) levels and leukocyte counts.From January to September 2014, healthy patients, aged between 18 (...) and 65 years, had elective thyroid surgery in the tertiary hospital. Eligible patients were randomized into either group D (dexamethasone 0.1 mg/kg IV) or group S (saline IV) after anesthesia induction. At the end of surgery, a drainage tube was placed at the thyroid bed with a negative pressure ball connected outside the wound. Drainage fluids were collected after thyroid surgery. The fluid volume and the levels of C-reactive protein and leukocyte counts inside were analyzed. All patients were

2019 EvidenceUpdates

10. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. (PubMed)

Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. Thyroid peroxidase antibodies are associated with an increased risk of miscarriage and preterm birth, even when thyroid function is normal. Small trials indicate that the use of levothyroxine could reduce the incidence of such adverse outcomes.We conducted a double-blind, placebo-controlled trial to investigate whether levothyroxine treatment would increase live-birth rates among euthyroid women who had thyroid (...) peroxidase antibodies and a history of miscarriage or infertility. A total of 19,585 women from 49 hospitals in the United Kingdom underwent testing for thyroid peroxidase antibodies and thyroid function. We randomly assigned 952 women to receive either 50 μg once daily of levothyroxine (476 women) or placebo (476 women) before conception through the end of pregnancy. The primary outcome was live birth after at least 34 weeks of gestation.The follow-up rate for the primary outcome was 98.7% (940 of 952

Full Text available with Trip Pro

2019 NEJM Controlled trial quality: predicted high

11. Repeat thyroid function tests for healthy older people are not needed. (PubMed)

Repeat thyroid function tests for healthy older people are not needed. The studyRoberts L, McCahon D, Johnson O, Haque MS, Parle J, Hobbs FR. Stability of thyroid function in older adults: the Birmingham Elderly Thyroid Study. Published on 28 August 2018 Br J Gen Pract 2018;68:e718-26.This study was funded by the National Institute for Health Research School for Primary Care Research (SPCR).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000703/repeat-thyroid

2019 BMJ

12. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model

Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

2019 NIHR HTA programme

13. High-intensity focused ultrasound for symptomatic benign thyroid nodules

High-intensity focused ultrasound for symptomatic benign thyroid nodules High-intensity focused ultr High-intensity focused ultrasound for asound for symptomatic benign th symptomatic benign thyroid nodules yroid nodules Interventional procedures guidance Published: 27 February 2019 nice.org.uk/guidance/ipg643 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) ultrasound for symptomatic benign thyroid nodules raises no major safety concerns, however the current evidence on its efficacy is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4governance, consent, and audit or research. 1.2 Clinicians wishing to do high-intensity focused ultrasound

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

14. Toxic thyroid adenoma

Toxic thyroid adenoma Toxic thyroid adenoma - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Toxic thyroid adenoma Last reviewed: February 2019 Last updated: February 2019 Summary Typically a single large thyroid nodule accompanied by clinical and biochemical hyperthyroidism. Diagnosis confirmed by thyroid scan demonstrating a hot area and suppression of extranodular thyroid tissue. Hyperthyroidism caused by toxic (...) adenomas generally does not remit. Definitive treatment, such as radioactive iodine therapy, is usually required. Complications of untreated toxic adenomas may include sequelae of hyperthyroidism such as cardiac dysfunction or bone loss, or tracheal compression by large nodules. Definition A toxic adenoma is an autonomously functioning thyroid nodule that causes hyperthyroidism. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management

2019 BMJ Best Practice

15. Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study

Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study A retrospective cohort study, supplemented with a nested case-control study, was performed using two administrative databases from commercial health plans in the United States to compare the incidence of pancreatic and thyroid cancer among users of exenatide versus other antidiabetic drugs (OADs). Patients with type 2 diabetes who initiated exenatide or OADs between 1 June 2005 and 30 June 2015 were (...) included. Pancreatic and thyroid cancers were identified using chart-validated algorithms in the cohort study. Cases in the nested case-control study were chart-confirmed pancreatic or thyroid cancers, and controls were sampled using risk-set sampling. The time-fixed analyses comparing 33 629 exenatide initiators with 49 317 propensity-score-matched OAD initiators yielded hazard ratios of 0.76 (95% confidence interval [CI] 0.47-1.21) for pancreatic cancer and 1.46 (95% CI 0.98-2.19) for thyroid cancer

2019 EvidenceUpdates

16. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial Two large randomised trials of patients with well-differentiated thyroid cancer reported in 2012 (HiLo and ESTIMABL1) found similar post-ablation success rates at 6-9 months between a low administered radioactive iodine (131I) dose (1·1 GBq) and the standard high dose (3·7 GBq (...) ). However, recurrence rates following radioactive iodine ablation have previously only been reported in observational studies, and recently in ESTIMABL1. We aimed to compare recurrence rates between radioactive iodine doses in HiLo.HiLo was a non-inferiority, parallel, open-label, randomised controlled factorial trial done at 29 centres in the UK. Eligible patients were aged 16-80 years with histological confirmation of differentiated thyroid cancer requiring radioactive iodine ablation (performance

2019 EvidenceUpdates

17. Thyroid hormone treatment does not help adults with mildly abnormal thyroid tests

Thyroid hormone treatment does not help adults with mildly abnormal thyroid tests Thyroid hormone treatment does not help adults with subclinical hypothyroidism Discover Portal Discover Portal Thyroid hormone treatment does not help adults with mildly abnormal thyroid tests Published on 8 January 2019 doi: There appears to be no benefit from treating adults with subclinical hypothyroidism. Treatment has no effect on quality of life or symptoms compared with placebo or no treatment. Thyroid (...) evidence that hormone treatment of subclinical hypothyroidism, gives no measurable benefit either. This may help inform practice, spare patients unnecessary treatment, and save NHS resources. Share your views on the research. Why was this study needed? Hypothyroidism is a condition where the thyroid gland doesn’t produce enough hormones, which can have various underlying causes. Hypothyroidism is characterised by low blood levels of free thyroxine (T4) and high levels of thyroid stimulating hormone

2019 NIHR Dissemination Centre

18. Repeat thyroid function tests for healthy older people are not needed

Repeat thyroid function tests for healthy older people are not needed Repeat thyroid function tests for healthy older people are not needed Discover Portal Discover Portal Repeat thyroid function tests for healthy older people are not needed Published on 2 January 2019 doi: Older adults with normal thyroid function or subclinical thyroid dysfunction show notable long-term stability of their thyroid hormone levels. This suggests that it is safe for GPs not to routinely retest older adults unless (...) they have risk factors or develop clinical symptoms of overt thyroid dysfunction. Over five years, about 0.2% older adults with normal thyroid function will develop overt hypothyroidism and about 3.5% will develop subclinical hypothyroidism. Amongst those with subclinical hypothyroidism, about 2% will develop overt hypothyroidism. The NIHR funded this study as there is a lack of consensus on the relevance of subclinical thyroid dysfunction and the need for repeat testing. This could both reduce

2019 NIHR Dissemination Centre

19. Treating subclinical thyroid dysfunction in pregnancy probably has no benefit

Treating subclinical thyroid dysfunction in pregnancy probably has no benefit Treating subclinical thyroid dysfunction in pregnancy probably has no benefit Discover Portal Discover Portal Treating subclinical thyroid dysfunction in pregnancy probably has no benefit Published on 8 August 2017 doi: Testing for and then treating pregnant women with mild or “subclinical” underactive thyroid did not improve pregnancy outcomes, newborn baby outcomes, or the child’s IQ at three to five years (...) . A clearly underactive thyroid (clinical hypothyroidism) in pregnancy has been linked with various adverse outcomes for the mother and baby, including pre-eclampsia, preterm birth, congenital defects and neurodevelopmental delay. This needs treatment. However, there has been debate around the harms and benefits from treating only mildly abnormal blood test results in women who do not show signs of thyroid problems, subclinical hypothyroidism. These two linked trials randomised 1,203 women with borderline

2019 NIHR Dissemination Centre

20. Intraoperative neuromonitoring versus visual nerve identification for prevention of recurrent laryngeal nerve injury in adults undergoing thyroid surgery. (PubMed)

Intraoperative neuromonitoring versus visual nerve identification for prevention of recurrent laryngeal nerve injury in adults undergoing thyroid surgery. Injuries to the recurrent inferior laryngeal nerve (RILN) remain one of the major post-operative complications after thyroid and parathyroid surgery. Damage to this nerve can result in a temporary or permanent palsy, which is associated with vocal cord paresis or paralysis. Visual identification of the RILN is a common procedure to prevent (...) nerve injury during thyroid and parathyroid surgery. Recently, intraoperative neuromonitoring (IONM) has been introduced in order to facilitate the localisation of the nerves and to prevent their injury during surgery. IONM permits nerve identification using an electrode, where, in order to measure the nerve response, the electric field is converted to an acoustic signal.To assess the effects of IONM versus visual nerve identification for the prevention of RILN injury in adults undergoing thyroid

Full Text available with Trip Pro

2019 Cochrane